Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Unknown status
National Cancer Institute (NCI)
Phase 3
2000-02-01
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may
fight prostate cancer by reducing the production of androgens. Radiation therapy uses
high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone
therapy and radiation therapy is more effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of
hormone therapy and radiation therapy in treating patients who have prostate cancer.
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Unknown status
Radiation Therapy Oncology Group
Phase 3
2000-02-01
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may
fight prostate cancer by reducing the production of androgens. Radiation therapy uses
high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone
therapy and radiation therapy is more effective for prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of
hormone therapy and radiation therapy in treating patients who have prostate cancer.
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Completed
Medarex
Phase 2
2004-06-01
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such
as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of
androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry cancer-killing substances to them. Giving
antihormone therapy together with ipilimumab may kill more tumor cells.
PURPOSE: This randomized phase II trial is study how well giving hormone therapy and
ipilimumab together works in treating patients with advanced prostate cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
